Erythropoietin in Management of Neonatal Hypoxic Ischemic Encephalopathy
Hypoxic-Ischemic Encephalopathy
About this trial
This is an interventional treatment trial for Hypoxic-Ischemic Encephalopathy
Eligibility Criteria
Inclusion Criteria:
- ≥ 36 weeks of gestational age.
- whole body cooling within 6 hours after birth.
Perinatal depression based on at least one of the following:
- Apgar score < 5 at 10 minutes.
- Need for resuscitation at 10 minutes.
- pH < 7.1 in cord and Base deficit ≥ 15 mmol/L.
- Moderate or severe encephalopathy according to sernat and sernat staging.
Exclusion Criteria:
1-Admitted after 24 hour of birth. 2-Birth weight < 1800 g (e.g., intrauterine growth restriction) 3-Genetic or congenital condition that affects neurodevelopment. 3-Torch infection and neonatal sepsis. 4-complex congenital heart disease. 5-severe dysmorphic feature . 6-Microcephaly:Head circumference < 2 stander deviations below mean for gestational age.
7-Polycythemia (hematocrit > 65%). 8-Premature rupture of membrane or chorioamnionitis.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
study group
control group
Within 4 to 6 hours after birth all cases with moderate to severe hypoxic ischemic encephalopathy will be enrolled in therapeutic hypothermia using total body cooling and temperature and Receive erythropoietin (1000 U/kg intravenously) on days 1, 2, 3, 5 ,7 and 9 (six doses,first two doses will be daily from the first day and last 4 doses will be every 2 days)
Within 4 to 6 hours after birth cases with moderate to severe hypoxic ischemic encephalopathy enrolled in therapeutic hypothermia using total body cooling and temperature and Receive normal saline on days 1, 2, 3, 5 ,7 and 9 (six doses,first two doses will be daily from the first day and last 4 doses will be every 2 days)